182 related articles for article (PubMed ID: 23353723)
1. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Chavez AH; Scott Coffield K; Hasan Rajab M; Jo C
Asian J Androl; 2013 Mar; 15(2):246-8. PubMed ID: 23353723
[TBL] [Abstract][Full Text] [Related]
2. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
3. [Approaches to medical management of patients with high risk of progressing of benign prostatic hyperplasia depending on concomitant erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2018 Jul; (3):70-77. PubMed ID: 30035422
[TBL] [Abstract][Full Text] [Related]
4. PDE-5i Management of Erectile Dysfunction After Rectal Surgery: A Systematic Review Focusing on Treatment Efficacy.
Notarnicola M; Celentano V; Gavriilidis P; Abdi B; Beghdadi N; Sommacale D; Brunetti F; Coccolini F; de'Angelis N
Am J Mens Health; 2020; 14(5):1557988320969061. PubMed ID: 33111645
[TBL] [Abstract][Full Text] [Related]
5. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
6. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients.
Frederick LR; Cakir OO; Arora H; Helfand BT; McVary KT
J Sex Med; 2014 Oct; 11(10):2546-53. PubMed ID: 25059314
[TBL] [Abstract][Full Text] [Related]
7. The Phosphodiasterase 5-Inhibitors (PDE-5i) for Erectile Dysfunction (ED): A Therapeutic Challenge For Psychiatrists.
Koon CS; Sidi H; Kumar J; Xi OW; Das S; Hatta MH; Alfonso C
Curr Drug Targets; 2018; 19(12):1366-1377. PubMed ID: 28215172
[TBL] [Abstract][Full Text] [Related]
8. [Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].
Jin Z; Xin ZC
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Aug; 43(4):632-5. PubMed ID: 21844982
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of psychological interventions alone, or in combination with phosphodiesterase-5 inhibitors, for the treatment of erectile dysfunction:A systematic review.
Atallah S; Haydar A; Jabbour T; Kfoury P; Sader G
Arab J Urol; 2021; 19(3):310-322. PubMed ID: 34552782
[No Abstract] [Full Text] [Related]
10. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
11. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
[TBL] [Abstract][Full Text] [Related]
12. Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis.
Duun-Henriksen AK; Dehlendorff C; Røder MA; Skriver C; Pottegård A; Friis S; Brasso K; Larsen SB
Acta Oncol; 2022 Aug; 61(8):931-938. PubMed ID: 35666094
[TBL] [Abstract][Full Text] [Related]
13. [PDE-5i combined with RigiScan-based audiovisual sexual stimulation test versus nocturnal penile tumescence test in evaluation of erectile function].
Sun XL; Ashok R; Gao QQ; Song T; Yu W; Xu ZP; Sun GH; Dai YT
Zhonghua Nan Ke Xue; 2020 Jul; 26(7):601-604. PubMed ID: 33377714
[TBL] [Abstract][Full Text] [Related]
14. [New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
Akhvlediani ND; Matyukhov IP
Urologiia; 2016 Nov; (5):52-56. PubMed ID: 28248021
[TBL] [Abstract][Full Text] [Related]
15. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
Xu Z; Jia RP
Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
[TBL] [Abstract][Full Text] [Related]
16. [Vacuum therapy for erectile dysfunction that fails to respond to PDE-5i: report of 70 cases].
Li P; Shen YJ; Liu TQ; Ma M; Zhang SJ; Wang YX; Tian RH; Chen HX; Ping P; Chen XF; Li Z; Li Z
Zhonghua Nan Ke Xue; 2013 Mar; 19(3):236-40. PubMed ID: 23700730
[TBL] [Abstract][Full Text] [Related]
17. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA.
Mulhall JP; Luo X; Zou KH; Stecher V; Galaznik A
Int J Clin Pract; 2016 Dec; 70(12):1012-1018. PubMed ID: 28032424
[TBL] [Abstract][Full Text] [Related]
18. [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
Kamalov AA; Takhirzade AM
Urologiia; 2017 Dec; (6):160-163. PubMed ID: 29376615
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
20. Association Between Erectile Dysfunction and Subsequent Prostate Cancer Development: A Population-Based Cohort Study With Double Concurrent Comparison Groups.
Kok VC; Hsiao YH; Horng JT; Wang KL
Am J Mens Health; 2018 Sep; 12(5):1492-1502. PubMed ID: 29708021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
